Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor &#945; Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.

Höyhtyä, Miikka; Korpela, Katri; Saqib, Schahzad; Junkkari, Sofia; Nissilä, Eija; Nikkonen, Anne; Dikareva, Evgenia; Salonen, Anne; de Vos, Willem M; Kolho, Kaija-Leena

Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.

Höyhtyä, Miikka; Korpela, Katri; Saqib, Schahzad; Junkkari, Sofia; Nissilä, Eija; Nikkonen, Anne; Dikareva, Evgenia; Salonen, Anne; de Vos, Willem M; Kolho, Kaija-Leena.

Afiliación

Höyhtyä M; Departmentof Pediatrics, Tampere University Hospital, Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
Korpela K; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Saqib S; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Junkkari S; Departmentof Pediatrics, Tampere University Hospital, Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.
Nissilä E; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Nikkonen A; Children's Hospital, Department of Pediatric Gastroenteroloy, Helsinki University, Helsinki, Finland.
Dikareva E; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Salonen A; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
de Vos WM; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Kolho KL; Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.

Inflamm Bowel Dis ; 29(1): 116-124, 2023 01 05.

Article en En | MEDLINE | ID: mdl-36040412

We studied absolute and relative abundances of fecal microbiota in relation to response to induction therapy with infliximab in pediatric inflammatory bowel disease. We discovered that a high absolute abundance of anti-inflammatory Bifidobacteriales at baseline associated with response.

Asunto(s)

Enfermedades Inflamatorias del Intestino; Microbiota; Humanos; Niño; Infliximab/uso terapéutico; Factor de Necrosis Tumoral alfa; Inhibidores del Factor de Necrosis Tumoral; Enfermedades Inflamatorias del Intestino/tratamiento farmacológico; Heces/química; Complejo de Antígeno L1 de Leucocito/análisis

Palabras clave

Crohn's disease; children; ulcerative colitis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Microbiota Límite: Child / Humans Idioma: En Revista: Inflamm Bowel Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google